Brain Matters Research

Delray Beach, Florida 33445

4 studies enrolling now · 90 studies all time

What they study most

AD, Age-Related Cognitive Decline, Age-Related Memory Disorders, Agitation Associated With Alzheimer's Dementia, Alzheimer Disease, Alzheimer Disease (AD), Alzheimer Disease 1, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14

Studies at this site

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease — Recruiting now
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) — Recruiting now
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease — Recruiting now
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia — Recruiting now
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia — Recruiting now
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss — Completed
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) — Running, not enrolling
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) — Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) — Completed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Running, not enrolling
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease — Completed
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid — Running, not enrolling
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) — Running, not enrolling
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) — Running, not enrolling
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease — Running, not enrolling
A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease — Stopped early
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) — Completed
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease — Completed
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease — Running, not enrolling
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) — Running, not enrolling
Memory Improvement Through Nicotine Dosing (MIND) Study — Completed
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease — Running, not enrolling
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease — Stopped early
Alzheimer's Plasma Extension — Running, not enrolling
Open-label Extension for Phase 3 Clinical Trials of Simufilam — Stopped early
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients — Completed
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects — Completed
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) — Completed
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD — Completed
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD) — Completed
TRC-PAD Program: In-Clinic Trial-Ready Cohort — Completed
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease — Completed
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) — Enrolling by invitation
Lomecel-B Effects on Alzheimer's Disease — Completed
Study of BHV-4157 in Alzheimer's Disease — Completed
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study — Completed
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) — Stopped early
GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease — Completed
A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease — Paused
To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia — Stopped early
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease — Stopped early
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease — Completed
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance — Stopped early
Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease — Completed
First in Human Study for Safety and Tolerability of AL003. — Completed